XML 36 R23.htm IDEA: XBRL DOCUMENT

Subsequent events	6 Months Ended
Subsequent events	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent events	Subsequent events In July 2021, the Company and National Resilience, Inc. ("Resilience") announced a strategic manufacturing collaboration aimed to accelerate the early research, development, and delivery of cell therapies. As part of the agreement, Resilience will acquire the Company's manufacturing facility located in Durham, North Carolina upon closing, and is expected to retain all staff currently employed at the site. Following closing, Resilience is expected to continue to support vector supply for both bluebird bio, Inc. and 2seventy bio, Inc. upon the closing of the spin-off transaction, which is expected by the end of 2021. In late July 2021, the Company made the decision to focus its efforts on the U.S. market for beti-cel, eli-cel, and LentiGlobin for SCD and plans to execute an orderly wind down of its European operations. It has commenced its assessment of the financial impact of this decision and anticipates disclosing the impact within its Quarterly Report on Form 10-Q for the third quarter of 2021.